

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	4	"766752".ap.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/12/01 10:29
L2	482	wound with closure and chronic with ulcer	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/12/01 10:36
L3	43	wound with closure same chronic with ulcer	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/12/01 10:36
L4	0	wound with closure same chronic with ulcer and 530/350.ccls.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/12/01 10:36
L5	4	wound with closure same chronic with ulcer and 514/12.ccls.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/12/01 10:37
L6	1	wound with closure same chronic with ulcer and 514/13.ccls.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/12/01 10:37
L7	0	wound with closure same chronic with ulcer and 514/14.ccls.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/12/01 10:37
L8	0	wound with closure same chronic with ulcer and 514/17.ccls.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/12/01 10:37
S1	2	"6146824".pn.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 14:50
S2	0	"6146824".pn. and skin with ulcer	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 14:50
S3	1	"6146824".pn. and healing	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:05
S4	1	"6146824".pn. and healing and treatment	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 16:12

S5	1	"6146824".pn. and healing and treatment and administering	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 16:42
S6	0	"6146824".pn. and healing and treatment and administering and contacting	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:05
S7	0	"6146824".pn. and healing and treatment and administering and ulcer	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:12
S8	2	"6184341".pn.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:14
S9	0	"6184341".pn. and ulcer	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:13
S10	5727	"6184341".pn. healing and treatment and administering and contacting	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:13
S11	0	"6184341".pn. and healing and treatment and administering and contacting	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:13
S12	0	"6184341".pn. and healing and treatment and administering	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:14
S13	0	"6184342".pn. and healing and treatment and administering	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:14
S14	2	"6184342".pn.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:14
S15	0	"09644038".pn.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:16
S16	3	"6602978".pn.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:16

S17	0	"6602978".pn. and dermal	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:17
S18	2	"6602978".pn. and wound with healing	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:19
S19	0	"6602978".pn. and wound with healing and treatment and administering and ulcer	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:19
S20	0	"6602978".pn. and wound with healing and treatment and administering	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:19
S21	0	"6602978".pn. and wound with healing and administering	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 15:20
S22	0	"09777328".ap.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 16:05
S23	5	"777328".ap.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 16:05
S24	3	"6602978".pn.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 16:09
S25	0	"09904090".ap.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 16:20
S26	4	"904090".ap.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 16:20
S27	1	"6146824".pn. and healing and treatment and administering and wound	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 16:42
S28	2	"6627731".pn.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 16:48

S29	2	"6627731".pn. and wound	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/04/04 16:48
-----	---	-------------------------	--	----	----	------------------

L2 QUE CHRONIC (W) SKIN (W) ULCER AND ADMISITERING

```
=> chronic (w) skin (w) ulcer and administering
    2 FILE CAPLUS
27 FILES SEARCHED...
    3 FILE IFIPAT
    1 FILE PROMT
62 FILES SEARCHED...
    77 FILE USPATFULL
    8 FILE USPAT2
    6 FILE WPIDS
    6 FILE WPINDEX
```

7 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L3 QUE CHRONIC (W) SKIN (W) ULCER AND ADMINISTERING

```
=> chronic (w) skin (w) ulcer and treatment
    1 FILE ADISINSIGHT
    1 FILE ADISNEWS
    3 FILE BIOBUSINESS
    2 FILE BIOCOMMERCE
28 FILES SEARCHED...
    28 FILE BIOSIS
    5 FILE BIOTECHNO
    2 FILE CABA
    5 FILE CANCERLIT
    7 FILE CAPLUS
    3 FILE CEABA-VTB
    1 FILE CEN
    9 FILE CIN
    4 FILE DDFB
    1 FILE DDFU
    36 FILE DGENE
27 FILES SEARCHED...
    1 FILE DISSABS
    4 FILE DRUGB
    4 FILE DRUGU
    1 FILE EMBAL
    37 FILE EMBASE
    6 FILE ESBIOWBASE
    5 FILE FEDRIP
    9 FILE IFIPAT
    4 FILE IMSDRUGNEWS
    5 FILE IMSRESEARCH
    8 FILE JICST-EPLUS
    1 FILE LIFESCI
    44 FILE MEDLINE
    13 FILE PASCAL
54 FILES SEARCHED...
    2 FILE PHAR
    8 FILE PHARMAML
    27 FILE PHIN
    101 FILE PROMT
    19 FILE SCISEARCH
    8 FILE TOXCENTER
    126 FILE USPATFULL
    11 FILE USPAT2
    1 FILE VETU
    23 FILE WPIDS
    23 FILE WPINDEX
```

40 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L4 QUE CHRONIC (W) SKIN (W) ULCER AND TREATMENT

```
=> d rank
F1      126  USPATFULL
F2      101  PROMT
F3       44  MEDLINE
F4       37  EMBASE
F5       36  DGENE
F6       28  BIOSIS
F7       27  PHIN
F8       23  WPIDS
F9       23  WPIINDEX
F10     19   SCISEARCH
F11     13   PASCAL
F12     11   USPAT2
F13      9   CIN
F14      9   IFIPAT
F15      8   JICST-EPLUS
F16      8   PHARMAML
F17      8   TOXCENTER
F18      7   CAPLUS
F19      6   ESBIOBASE
F20      5   BIOTECHNO
F21      5   CANCERLIT
F22      5   FEDRIP
F23      5   IMSRESEARCH
F24      4   DDFB
F25      4   DRUGB
F26      4   DRUGU
F27      4   IMSDRUGNEWS
F28      3   BIOBUSINESS
F29      3   CEABA-VTB
F30      2   BIOCOMMERCE
F31      2   CABA
F32      2   PHAR
F33      1   ADISINSIGHT
F34      1   ADISNEWS
F35      1   CEN
F36      1   DDFU
F37      1   DISSABS
F38      1   EMBAL
F39      1   LIFESCI
F40      1   VETU
```

```
=> file medline biosis caplus
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY           SESSION
FULL ESTIMATED COST          7.08            7.88
```

FILE 'MEDLINE' ENTERED AT 11:28:19 ON 01 DEC 2005

FILE 'BIOSIS' ENTERED AT 11:28:19 ON 01 DEC 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 11:28:19 ON 01 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

```
=> chronic (w) skin (w) ulcer and treatment
L5          79 CHRONIC (W) SKIN (W) ULCER AND TREATMENT
```

```
=> dup remove
ENTER L# LIST OR (END):15
```

PROCESSING COMPLETED FOR L5

L6 60 DUP REMOVE L5 (19 DUPLICATES REMOVED)

=> chronic (w) skin (w) ulcer and treatment and peptide

L7 6 CHRONIC (W) SKIN (W) ULCER AND TREATMENT AND PEPTIDE

=> d ti 1-6

L7 ANSWER 1 OF 6 MEDLINE on STN

TI Progranulin is a mediator of the wound response.

L7 ANSWER 2 OF 6 MEDLINE on STN

TI Successful **treatment** of itching and atopic eczema by transcutaneous nerve stimulation.

L7 ANSWER 3 OF 6 MEDLINE on STN

TI **Treatment of chronic skin ulcers**
by a proteolytic enzyme-antibiotic preparation.

L7 ANSWER 4 OF 6 MEDLINE on STN

TI ENZYMATIC TREATMENT OF CHRONIC SKIN
ULCERS.

L7 ANSWER 5 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

TI PROPERTIES AND USES OF BIOBRANE.

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

TI Progranulin is a mediator of the wound response

=> d ab bib 1-6

L7 ANSWER 1 OF 6 MEDLINE on STN

AB Annually, 1.25 million individuals suffer burns in the United States and 6.5 million experience **chronic skin ulcers**, often from diabetes, pressure or venous stasis. Growth factors are essential mediators of wound repair, but their success as therapeutics in wound **treatment** has, so far, been limited. Therefore, there is a need to identify new wound-response regulatory factors, but few have appeared in recent years. Progranulin (also called granulin or epithelin precursor, acrogranin or PC-derived growth factor) is a growth factor involved in tumorigenesis and development. **Peptides** derived from progranulin have been isolated from inflammatory cells, which led to suggestions that progranulin gene products are involved in the wound response, but this remains undemonstrated. We report that in murine transcutaneous puncture wounds, progranulin mRNA is expressed in the inflammatory infiltrate and is highly induced in dermal fibroblasts and endothelia following injury. When applied to a cutaneous wound, progranulin increased the accumulation of neutrophils, macrophages, blood vessels and fibroblasts in the wound. It acts directly on isolated dermal fibroblasts and endothelial cells to promote division, migration and the formation of capillary-like tubule structures. Progranulin is, therefore, a probable wound-related growth factor.

AN 2003053690 MEDLINE

DN PubMed ID: 12524533

TI Progranulin is a mediator of the wound response.

AU He Zhiheng; Ong Colin H P; Halper Jaroslava; Bateman Andrew

CS Division of Experimental Medicine, McGill University, and Endocrine Research Laboratory, Royal Victoria Hospital, Montreal, Quebec, Canada.

NC CA71023 (NCI)

SO Nature medicine, (2003 Feb) 9 (2) 225-9. Electronic Publication:

2003-01-13.

Journal code: 9502015. ISSN: 1078-8956.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200305
ED Entered STN: 20030204
Last Updated on STN: 20030513
Entered Medline: 20030509

L7 ANSWER 2 OF 6 MEDLINE on STN
AB Low-frequency (2 Hz) transcutaneous electrical nerve stimulation (TNS) may produce prolonged and widespread sympatho-inhibition resulting in improved skin microcirculation with increased skin temperature in patients with peripheral vascular insufficiency. The method has previously been used successfully to improve peripheral circulation in such patients and to accelerate healing of **chronic skin ulcers** of various etiology. The present report deals with healing of atopic eczema and relief of pruritus by low-frequency TNS treatment in a patient who was followed for 2 years, the first 8 months with daily recordings of the effects, and then for an additional 16 months during which period TNS only occasionally was used. TNS also produced increased plasma levels of ACTH, cortisol and vasoactive intestinal polypeptides (VIP). The mechanisms of the favourable clinical effects are discussed.

AN 88046026 MEDLINE
DN PubMed ID: 2890272
TI Successful treatment of itching and atopic eczema by transcutaneous nerve stimulation.
AU Bjorna H; Kaada B
CS Rogaland Central Hospital, Stavanger, Norway.
SO Acupuncture & electro-therapeutics research, (1987) 12 (2) 101-12.
Journal code: 7610364. ISSN: 0360-1293.
CY United States
DT (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198711
ED Entered STN: 19900305
Last Updated on STN: 19950206
Entered Medline: 19871127

L7 ANSWER 3 OF 6 MEDLINE on STN
AN 67092481 MEDLINE
DN PubMed ID: 6018377
TI Treatment of **chronic skin ulcers** by a proteolytic enzyme-antibiotic preparation.
AU Spencer M C
SO Journal of the American Geriatrics Society, (1967 Mar) 15 (3) 219-23.
Journal code: 7503062. ISSN: 0002-8614.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 196704
ED Entered STN: 19900101
Last Updated on STN: 19900101
Entered Medline: 19670413

L7 ANSWER 4 OF 6 MEDLINE on STN
AN 65114997 MEDLINE
DN PubMed ID: 14310347
TI ENZYMATIC TREATMENT OF CHRONIC SKIN ULCERS.
AU SPENCER M C
SO JAMA : journal of the American Medical Association, (1965 Jul 26) 193

272-4.

Journal code: 7501160. ISSN: 0098-7484.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS OLDMEDLINE; NONMEDLINE

EM 199612

ED Entered STN: 19990716

Last Updated on STN: 19990716

Entered Medline: 19961201

L7 ANSWER 5 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AB Biobrane is a biosynthetic skin prosthesis, that was developed by Woodroof and Tavis in 1979. It consists of 25 μ thickness silicone membrane with a laminated nylon fabric linked to porcine collagen **peptides**.

Biobrane has been commercially available for the **treatment** burn wounds, and for skin and flap donor sites. Biobrane has the following good properties as a skin substitute: 1) good adherence and pain relief; 2) flexibility; 3) control of evaporative water loss; 4) works as a bacterial barrier; 5) good air and water permeability; 6) sterile (nonpyrogenic, nonviral); 7) available and easy to store. Biobrane can be applied to skin and flap donor sites, fresh superficial burns, excised deep burns, meshed, autografted wounds, and to well-debrided deep and **chronic skin ulcers**.

AN 1990:309915 BIOSIS

DN PREV199090028882; BA90:28882

TI PROPERTIES AND USES OF BIOBRANE.

AU MINAKAWA H [Reprint author]; OHURA T

CS DEP PLASTIC SURG, SCH MED, HOKKAIDO UNIV, SAPPORO 060

SO Japanese Journal of Plastic and Reconstructive Surgery, (1990) Vol. 33, No. 4, pp. 311-316.

CODEN: KEGEAC. ISSN: 0021-5228.

DT Article

FS BA

LA JAPANESE

ED Entered STN: 10 Jul 1990

Last Updated on STN: 10 Jul 1990

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

AB Annually, 1.25 million individuals suffer burns in the United States and 6.5 million experience **chronic skin ulcers**, often from diabetes, pressure or venous stasis. Growth factors are essential mediators of wound repair, but their success as therapeutics in wound **treatment** has, so far, been limited. Therefore, there is a need to identify new wound-response regulatory factors, but few have appeared in recent years. Progranulin (also called granulin or epithelin precursor, acrogranin or PC-derived growth factor) is a growth factor involved in tumorigenesis and development. **Peptides** derived from progranulin have been isolated from inflammatory cells, which led to suggestions that progranulin gene products are involved in the wound response, but this remains undemonstrated. We report that in murine transcutaneous puncture wounds, progranulin mRNA is expressed in the inflammatory infiltrate and is highly induced in dermal fibroblasts and endothelia following injury. When applied to a cutaneous wound, progranulin increased the accumulation of neutrophils, macrophages, blood vessels and fibroblasts in the wound. It acts directly on isolated dermal fibroblasts and endothelial cells to promote division, migration and the formation of capillary-like tubule structures. Progranulin is, therefore, a probable wound-related growth factor.

AN 2003:83027 CAPLUS

DN 138:348997

TI Progranulin is a mediator of the wound response

AU He, Zhiheng; Ong, Colin H. P.; Halper, Jaroslava; Bateman, Andrew

CS Division of Experimental Medicine, Royal Victoria Hospital and Endocrine

SO Research Laboratory, Montreal McGill University, Montreal, QC, Can.
Nature Medicine (New York, NY, United States) (2003), 9(2), 225-229
CODEN: NAMEFI; ISSN: 1078-8956

PB Nature Publishing Group
DT Journal
LA English

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT .